Updated on 21 August 2026
Integrated platform-based innovative biopharma for inhalation formulations
Chairperson & CEO at CF PharmTech, Inc. 长风药业股份有限公司
China
About
Our Mission
Rooted in an integrated China-global innovation ecosystem, we build on high-value complex formulations, pioneer breakthrough innovative drugs, and are driven by proprietary delivery technologies to address the world’s most urgent unmet clinical needs.
Device engineering, precision drug delivery, global regulatory filing and commercialization
As a global innovator in inhalation drug delivery technology, CF is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs.
Fully self-developed, globally integrated end-to-end capabilities
From breath-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms, the Company is systematically advancing its innovation pipeline targeting the Chinese, U.S. and European markets.
In-depth Layout in Therapeutic Areas
We maintain an in-depth layout in respiratory diseases (asthma, COPD and bronchiectasis) and rhinological diseases (allergic rhinitis and chronic sinusitis). We also strategically expand into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system diseases, taking the lead in exploring the cutting-edge frontier of precise drug delivery via the nose-to-brain pathway.
CF has established an extensively covered three-dimensional commercial network in China. With a globally compliant manufacturing system and deepening overseas layout, it is steadily advancing towards the development goal of becoming a global innovative pharmaceutical enterprise.
Project Location
- China
Project Website
https://www.cfpharmtech.com/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Manufacturing
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Type(s) of Last Financing Round of the project (if Applicable)
- Secondary Market Financing
Main Service(s) Required
- Financial Services
Financial Services
- Institutional Investment
Similar opportunities
Project
Integrated platform-based innovative biopharma for inhalation formulations
- Yes
- Yes
- Bio-Tech
- Manufacturing
- Private Project
- Health Technology
- Medical Technology
- Financial Services
- Institutional Investment
- Secondary Market Financing
- Investment / Financing Discussion
Ting Su
IR at CF PharmTech, Inc. 长风药业股份有限公司
China
Project
Integrated platform-based innovative biopharma for inhalation formulations
- Yes
- Yes
- Bio-Tech
- Operations
- Manufacturing
- Private Project
- Health Technology
- Medical Technology
- Financial Services
- Equal Shareholdings
- Majority Shareholdings
- Minority Shareholdings
- Direct Equity Investment
- Secondary Market Financing
- M&A / Strategic Acquisition Opportunity
Yuyu Zhu
副总经理 at CF PharmTech, Inc. 长风药业股份有限公司
China
Project
Focusing on microRNA drug development and PDEV delivery system
- No
- Yes
- Technology
- Operations
- Private Project
- Equity (private)
- Transportation Services
- Information Technology Services
Yang Chao Chen
Director at Golden Biotech Limited
China (Hong Kong)